Triox Limited Announces Closing of Initial Public Offering


CALGARY, ALBERTA--(Marketwire - June 29, 2012) -

This news release does not constitute an offer to sell or a solicitation of any offer to buy the common shares in the United States. The common shares have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption for the registration requirements of such Act.

Triox Limited ("Triox" or the "Company") (TSX VENTURE:TTL.P) is pleased to announce that it has successfully completed its initial public offering ("Offering") raising gross proceeds of $230,000 pursuant to a prospectus dated June 7, 2012. An aggregate of 2,300,000 ordinary shares in the capital of the Company (the "Shares") were subscribed for at a price of $0.10 per Share. The Company has received permission from the TSX Venture Exchange (the "Exchange") to list the Shares on June 29, 2012, but the Shares will be immediately halted pending receipt by the Exchange of satisfactory documentation. The Shares will trade under the stock symbol TTL.P.

Mackie Research Capital Corporation (the "Agent") acted as the agent for the Offering. The Agent received a cash commission equal to 10% of the gross proceeds of the Offering and an option to purchase 230,000 Shares at a price of $0.10 per Share for a period of 24 months from the date of listing of the Shares on the Exchange. The Agent also received a corporate finance fee of $10,000.

Upon closing of the Offering, Triox granted 1,118,847 incentive stock options to its directors and officers which are exercisable within ten years from the date of the grant at an exercise price of $0.10 per Share. As a result of the closing of its initial public offering, Triox now has 11,300,000 Shares issued and outstanding (9,000,000 of which are subject to escrow restrictions).

About the Company

Triox is a capital pool corporation ("CPC") within the meaning of the policies of the Exchange that has not commenced commercial operations and has no assets other than cash. The board of directors of Triox consists of James Varanese, Jason Krueger, Bruce Gaston, Dr. John Cubitt, Jason Rosychuk and Robb McNaughton. The officers of the Company are Dr. John Cubitt and Bruce Gaston. Except as specifically contemplated in the Exchange CPC policy, until the completion of its Qualifying Transaction, the Company will not carry on business, other than the identification and evaluation of companies, business or assets with a view to completing a proposed Qualifying Transaction.

Forward Looking Information

This news release contains statements about Triox's expectations regarding the completion of the application for listing and the commencement of trading on the Exchange that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although Triox believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include failure to list. The forward-looking statements contained in this press release are made as of the date hereof, and Triox undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Contact Information:

Triox Limited
Dr. John Cubitt
President and Chief Executive Officer
Rooms 1307-9 Dominion Centre
43-59 Queen's Road East, Wanchai, Hong Kong
+44 77 1443-0171